STAT Plus: Flawed trials supported half of recent approvals of cancer drugs in Europe, study says
ALEX HOGAN/STAT
Randomized, controlled trials accounted for about 90% of pivotal studies from 2009 to 2013 but only 75% of studies from 2014 to 2016.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario